Conditions: Autosomal Dominant Polycystic Kidney Disease （ADPKD)
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 135
Healthy volunteers: no

Brief summary:
ADPKD patients who enrolled in Trial 156-04-251 will receive repeated oral administration of tolvaptan twice daily (morning and evening: 45mg/15mg, 60mg/30mg, or 90mg/30mg).

Detailed description:

Arms:
arm 1: Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.

Interventions: intervention 1: tolvaptan
Intervention descriptions: intervention 1: Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.

Protocol document: